217 related articles for article (PubMed ID: 22125931)
1. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Shetty VP; Wakade AV; Ghate SD; Pai VV
Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
[TBL] [Abstract][Full Text] [Related]
2. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
Katoch K; Katoch VM; Natarajan M; Gupta UD; Sharma VD; Singh HB
Indian J Lepr; 2008; 80(4):331-44. PubMed ID: 20329382
[TBL] [Abstract][Full Text] [Related]
3. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.
Shetty VP; Wakade AV; Ghate SD; Pai VV; Ganapati RR; Antia NH
Lepr Rev; 2005 Sep; 76(3):241-52. PubMed ID: 16248211
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
Kumar A; Girdhar A; Girdhar BK
Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
[TBL] [Abstract][Full Text] [Related]
5. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of single-dose chemotherapy (rifampicin, ofloxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial.
Manickam P; Nagaraju B; Selvaraj V; Balasubramanyam S; Mahalingam VN; Mehendale SM; Pannikar VK; Gupte MD;
Indian J Lepr; 2012; 84(3):195-207. PubMed ID: 23484334
[TBL] [Abstract][Full Text] [Related]
7. A study on trend of relapse in leprosy and factors influencing relapse.
Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
[TBL] [Abstract][Full Text] [Related]
8. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
9. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
12. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
14. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
15. A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions.
2-3 Lesion Multicentre Trial Group
Indian J Lepr; 2001; 73(2):131-43. PubMed ID: 11579649
[TBL] [Abstract][Full Text] [Related]
16. A comparative clinico-pathological study of single dose ROM in paucibacillary leprosy patients with 1-3 skin lesions.
Deshmukh AR; Dhurat RS; Jerajani HR
Indian J Lepr; 2003; 75(3):209-17. PubMed ID: 15267190
[TBL] [Abstract][Full Text] [Related]
17. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
20. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
